The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated data at the 2026 AAN Annual Meeting, with Phase 3 dosing targeted for the first half of this year
Newsflash:
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build …
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated data at the 2026 AAN Annual Meeting, with Phase 3 dosing targeted for the first half of this year
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build …
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated data at the 2026 AAN Annual Meeting, with Phase 3 dosing targeted for the first half of this year
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated data at the 2026 AAN Annual Meeting, with Phase 3 dosing targeted for the first half of this year
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated data at the 2026 AAN Annual Meeting, with Phase 3 dosing targeted for the first half of this year
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention for close …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery history, targeting first-in-human studies for its internally generated candidates before year-end 2026.
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
Arvinas’ vepdegestrant (VEPPANU) demonstrated a 43% reduction in risk of disease progression versus fulvestrant in the pivotal VERITAC-2 trial, earning a landmark approval as the first proteolysis-targeting chimera to reach patients
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a CNS platform that extends well beyond its blockbuster GLP-1 franchise
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?